ReviewPediatric blood & cancer2020
Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.
Review in Pediatric blood & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 44 citations in OpenAlex.
- Classifying Sickle Cell Disease Subtypes from Clinical Reports: Algorithm Validation and ICD-10 Accuracy Assessment in Five French Hospitals.Journal of medical systems · 2026Article
- Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease.JAMA network open · 2026Article
- Postpartum Long-Acting Reversible Contraception Use Among People With Sickle Cell Disease in the United States.O&G open · 2026Article
- Accurate identification of sickle cell disease cases in a large genotyped cohort using electronic health record data.Blood advances · 2026Article
- Cystic fibrosis and sickle cell disease associated with nonadministration of VTE prophylaxis in hospitalized adults.Blood advances · 2026Article
- Characteristics of outpatient nirmatrelvir/ritonavir recipients during the 2022/2023 era in Alberta, Canada: A retrospective observational population-based study.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014-2021.Annals of hematology · 2026Article
- High concordance of physician-attestation with manual data abstraction for sickle cell type: an ASH RC Data Hub study.Blood advances · 2026Article
- Article
- Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020.American journal of hematology · 2026Article
- Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada.Pharmacoepidemiology and drug safety · 2026Article
- Genotype Differences and Hydroxyurea Utilization Among Adults With Moderate to Severe Sickle Cell Disease.Pharmacotherapy · 2026Article
- Postpartum Tubal Sterilization in Sickle Cell Disease in the 2012-2019 National Inpatient Sample.Journal of women's health (2002) · 2025Article
- Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.Journal of comparative effectiveness research · 2025Article
- Ten-year trends in opioid prescribing and vaso-occlusive crises in sickle cell disease: a population-based national cohort study (2011-2022).Lancet regional health. Americas · 2025Article
- Trends, Predictors, and Outcomes of Critically Ill Patients With Sickle Cell Disease in the United States.EJHaem · 2025Article
- Hospital Readmissions Among People With Sickle Cell Disease.JAMA network open · 2025Article
- Respiratory phenotype and health care utilization patterns by adults with sickle cell disease.Blood advances · 2025Article
- Clinical and Economic Burden of Managing Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Administratively reported fetal alcohol spectrum disorders in commercially- and Medicaid-insured samples of children in the United States, 2015 - 2021.Drug and alcohol dependence · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
To identify people living with sickle cell disease (SCD) and study their healthcare utilization, researchers can either use clinical records linked to administrative data or use billing diagnosis codes in stand-alone administrative databases. Correct identification of individuals clinically managed for SCD using diagnosis codes in claims databases is limited by the accuracy of billing codes in outpatient encounters. In this critical review, we assess the strengths and limitations of claims-based SCD case-finding algorithms in stand-alone administrative databases that contain both inpatient and outpatient records. Validation studies conducted using clinical records and newborn screening for confirmation of SCD case status have found that algorithms that require three or more nonpharmacy claims or one inpatient claim plus two or more outpatient claims with SCD codes show acceptable accuracy (positive predictive value and sensitivity) in children and adolescents. Future studies might seek to assess the accuracy of case-finding algorithms over the lifespan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.